For the quarter ending 2026-03-31, CMPS had $316,402K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss from operations | - | -179,037 | - | - |
| Fair value change of warrant liabilities | - | 38,163 | - | - |
| Benefit from r&d tax credit | - | -3,747 | - | - |
| Interest income | - | 7,182 | - | - |
| Interest expense | - | 4,517 | - | - |
| Foreign exchange gains (losses) | - | 3,471 | - | - |
| Other income | - | 1,380 | - | - |
| Research and development-Development Expenses | -44,756 | - | - | - |
| Research and development-Personnel Expenses | -11,806 | - | - | - |
| Research and development-Non Cash Share Based Compensation Expense | -3,102 | - | - | - |
| Research and development-Other Expenses | -2,386 | - | - | - |
| General and administrative-Personnel Expenses | -8,699 | - | - | - |
| General and administrative-Legal And Professional Fees | -10,644 | - | - | - |
| General and administrative-Facilities And Other Expenses | -4,047 | - | - | - |
| General and administrative-Non Cash Share Based Compensation Expense | -4,741 | - | - | - |
| Total operating expenses | -90,181 | - | - | - |
| Loss from operations | 90,181 | - | - | - |
| Fair value change of warrant liabilities | 215,314 | - | - | - |
| Benefit from r&d tax credit | -14,182 | - | - | - |
| Interest income | -3,453 | - | - | - |
| Interest expense | 1,915 | - | - | - |
| Foreign exchange (losses) gains | -4,335 | - | - | - |
| Other income | -526 | - | - | - |
| Income tax benefit (expense) | 11 | -2,212 | - | - |
| Net income (loss) | 91,202 | -93,878 | -193,984 | - |
| Depreciation | 0 | 6 | 15 | 195 |
| Non-cash interest | 261 | 364 | 336 | 768 |
| Non-cash gain on foreign currency remeasurement | 1,276 | 470 | -1,203 | 1,885 |
| Non-cash share-based compensation | 2,896 | 2,852 | 3,207 | 7,531 |
| Non-cash lease expenses | 518 | 1,296 | -55 | 1,169 |
| Transaction costs allocated to warrants | 643 | 0 | 0 | 5,778 |
| Fair value change of warrant liabilities | -130,916 | 38,163 | 84,398 | - |
| Prepaid expenses and other current assets | 3,625 | -14,126 | 2,995 | 14,369 |
| Deferred and prepaid tax assets | 347 | -776 | 238 | 515 |
| Other assets | 2,468 | 6,746 | -3,480 | 1,445 |
| Operating lease liabilities | -525 | -1,302 | 24 | -1,174 |
| Accounts payable | -4,177 | 9,753 | -5,382 | -2,337 |
| Accrued expenses and other liabilities | -122 | -2,728 | 1,698 | -4,875 |
| Net cash used in operating activities | -47,936 | -37,788 | -35,106 | -84,346 |
| Proceeds from the exercise of warrants | - | 0 | 0 | 0 |
| Proceeds from the vesting of restricted share units | - | 1 | - | - |
| Payments of withholding tax on stock award | - | 0 | 0 | 0 |
| Proceeds from the issuance of shares under the employee share purchase plan | - | 162 | 0 | 157 |
| Proceeds from issuance of ordinary shares and pre-funded warrants, net of issuance costs | 140,643 | 0 | 0 | 140,357 |
| Proceeds from the exercise of ads warrants-ADSWarrants | 87,871 | - | - | - |
| Proceeds from issuance of pre-funded warrants, net of issuance costs-ADSWarrants | 115,333 | - | - | - |
| Net proceeds from issuance of long term debt | 18,582 | - | - | - |
| Proceeds from exercise of options | 24 | 24 | 0 | 11 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs-Prefunded Warrants | 1 | - | - | - |
| Net cash provided by financing activities | 362,454 | 187 | 0 | 140,525 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,884 | 1,272 | -838 | 611 |
| Net increase in cash, cash equivalents and restricted cash | 316,402 | -36,329 | -35,944 | 56,790 |
| Cash, cash equivalents and restricted cash, beginning of the period | 149,987 | 186,316 | 165,470 | - |
| Cash, cash equivalents and restricted cash, end of the period | 466,389 | 149,987 | 186,316 | - |
COMPASS Pathways plc (CMPS)
COMPASS Pathways plc (CMPS)